Tesaglitazar

Tesaglitazar
Clinical data
ATC code	None;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name (2S)-2-Ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl); ethoxy]phenyl]propanoic acid;
CAS Number	251565-85-2 ;
PubChem CID	208901;
ChemSpider	180999 ;
UNII	6734037O3L;
KEGG	D01274 ;
ChEMBL	ChEMBL521632 ;
CompTox Dashboard (EPA)	DTXSID4048773 ;
ECHA InfoCard	100.201.079
Chemical and physical data
Formula	C20H24O7S
Molar mass	408.46 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCO[C@@H](CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O;
	InChI InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1 ; Key:CXGTZJYQWSUFET-IBGZPJMESA-N ;
	(what is this?) (verify)

Tesaglitazar (also known as AZ 242) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for the management of type 2 diabetes.^[1]

The drug had completed several phase III clinical trials,^[2] however in May, 2006 AstraZeneca announced that it had discontinued further development.^[3]

References

^ Wilding JP, Gause-Nilsson I, Persson A (2007). "Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes". Diab Vasc Dis Res. 4 (3): 194–203. doi:10.3132/dvdr.2007.040. PMID 17907109.
^ "GALIDA (tesaglitazar) Clinical Trial Report Summaries". AstraZeneca. Retrieved 2008-03-17. ^{[dead link]}
^ "AstraZeneca Discontinues Development of GALIDA (tesaglitazar)". AstraZeneca. 2006-05-04. Retrieved 2012-07-23.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[pmid17907109-1] Wilding JP, Gause-Nilsson I, Persson A (2007). "Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes". Diab Vasc Dis Res. 4 (3): 194–203. doi:10.3132/dvdr.2007.040. PMID 17907109.

[title-2] "GALIDA (tesaglitazar) Clinical Trial Report Summaries". AstraZeneca. Retrieved 2008-03-17. ^{[dead link]}

[AstraZeneca_tesaglitazar_press_release)-3] "AstraZeneca Discontinues Development of GALIDA (tesaglitazar)". AstraZeneca. 2006-05-04. Retrieved 2012-07-23.

[1]

[2]

[3]

v t e Receptor/signaling modulators
Amino acids and similar/related	Amino acids and related: GABA receptor modulators GABA_A receptor positive modulators GABA metabolism and transport modulators GHB receptor modulators Glutamate metabolism and transport modulators Glycine receptor modulators Ionotropic glutamate receptor modulators Metabotropic glutamate receptor modulators Monoamines: Adrenergic receptor modulators Dopamine receptor modulators Histamine receptor modulators Melatonin receptor modulators Monoamine metabolism modulators Monoamine neurotoxins Monoamine releasing agents Monoamine reuptake inhibitors Serotonin receptor modulators hTAAR modulators Acetylcholine: Acetylcholine metabolism and transport modulators Muscarinic acetylcholine receptor modulators Nicotinic acetylcholine receptor modulators Others: Imidazoline receptor modulators Purine receptor modulators Sigma receptor modulators Thyroid hormone receptor modulators
Lipids	Eicosanoids: Cannabinoid receptor modulators Leukotriene signaling modulators Prostanoid signaling modulators Phospholipids: Lysophospholipid signaling modulators PAF receptor modulators Steroids: Androgen receptor modulators Estrogen receptor modulators Glucocorticoid receptor modulators Mineralocorticoid receptor modulators Progesterone receptor modulators Steroid metabolism modulators Other nuclear receptors: Aryl hydrocarbon receptor modulators Estrogen-related receptor modulators FXR and LXR modulators PPAR modulators Retinoid receptor modulators Vitamin D receptor modulators Xenobiotic-sensing receptor modulators
Peptides/proteins	Peptides: Angiotensin receptor modulators GH/IGF-1 axis signaling modulators GnRH and gonadotropin receptor modulators Melanocortin receptor modulators Neurokinin receptor modulators Opioid receptor modulators Oxytocin and vasopressin receptor modulators Cytokines: Cytokine receptor modulators Chemokine receptor modulators Interleukin receptor modulators TNF receptor superfamily modulators Growth factors: Growth factor receptor modulators TGFβ receptor superfamily modulators
Others and non-receptor	Enzymes: Cytochrome P450 modulators Histone deacetylase inhibitors Phosphodiesterase inhibitors Ion channels: Ion channel modulators TRP channel modulators Transporters: Sodium-glucose transporter modulators Symporter inhibitors Others: Nitric oxide signaling modulators